Clinical Trials Directory

Trials / Conditions / HR+/HER2- Advanced Breast Cancer

HR+/HER2- Advanced Breast Cancer

11 registered clinical trials studyying HR+/HER2- Advanced Breast Cancer — 6 currently recruiting.

StatusTrialSponsorPhase
Not Yet RecruitingExploration of Dalpiciclib Plus HDACi in HR+/HER2- Advanced Breast Cancer After Failure of CDK4/6 Inhibitor
NCT06556862
Beijing 302 HospitalPhase 2
RecruitingORION-1: Study of AVZO-023 as a Single Agent and in Combination With AVZO-021, and/or Endocrine Therapy in Adv
NCT06998407
Avenzo Therapeutics, Inc.Phase 1 / Phase 2
WithdrawnA Real-World Study in Patients With HR+/HER2- Advanced Breast Cancer
NCT07076680
SciClone Pharmaceuticals—
RecruitingA Study of Invikafusp Alfa (STAR0602), a Selective T Cell Receptor (TCR)-Targeting, Bifunctional Antibody-fusi
NCT06827613
Marengo Therapeutics, Inc.Phase 1 / Phase 2
Not Yet RecruitingAlbumin-bound Paclitaxel、Dalpiciclib and AI in ER-Low (1%-10%) HER2-ABC
NCT06711094
Fujian Medical UniversityN/A
Active Not RecruitingA Prospective Non-interventional Study to Evaluate Clinical Outcomes of Ribociclib Combined With Endocrine The
NCT06625333
Novartis Pharmaceuticals—
Active Not RecruitingA Prospective NIS to Evaluate the Clinical Outcomes of Risarg® (Ribociclib) Combined With Endocrine Therapy or
NCT06148506
Novartis Pharmaceuticals—
RecruitingStudy of AVZO-021 in Patients With Advanced Solid Tumors
NCT05867251
Avenzo Therapeutics, Inc.Phase 1 / Phase 2
RecruitingChidamide/Everolimus for PIK3CA Wild-type/Mutant HR+/HER2- Advanced Breast Cancer
NCT05983107
Cancer Institute and Hospital, Chinese Academy of Medical SciencesPhase 2
Active Not RecruitingReal-world Study of Sacituzumab Govitecan Monotherapy or Combination Therapy in Recurrent or Metastatic HER2-n
NCT07018427
Peking University Cancer Hospital & Institute—
UnknownExploration of Dalpiciclib + Chidamide in HR+/HER2- Advanced Breast Cancer After Failure of CDK4/6 Inhibitor:
NCT05586841
Beijing 302 HospitalPhase 1